
Despite substantial progress in melanoma treatment between 2010 and 2014, recent advancements have slowed, with challenges in addressing resistance to BRAF/MEK and immune checkpoint therapies. While PD-1 antibodies transformed treatment, new therapeutic classes are deemed essential for significant patient outcome improvements. This slowdown contrasts the remarkable gains made in melanoma outcomes during the 2010s.
Like
Save
Share